⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients

Official Title: A Randomized, Placebo-controlled, Double-blinded, Phase II Study of Efficacy of Regorafenib as Maintenance Treatment in Patients With High Grade Bone Sarcomas at Diagnosis or Relapse and Without Complete Remission After Standard Treatment

Study ID: NCT04698785

Study Description

Brief Summary: This is a randomized, double-blinded, 2 arms study concerning patients with high-grade bone sarcoma (HGBS) without complete remission after standard treatment at diagnosis or first relapse. In the first arm, patients will be treated with regorafenib + best supportive care (BSC) for a maximum of 12 months as maintenance therapy after standard line therapy completion, whereas in the second arm, patients will be treated with placebo + BSC (standard of care). The comparison between this two arms will allow to determine whether or not regorafenib and BSC is efficient for disease control, in terms of Progression-Free Survival improvement.

Detailed Description: This is a randomized, placebo-controlled, double-blinded, prospective, comparative, multicentre phase II study. Patients with measurable unresectable residual disease will be accrued after they completed standard of care, consisting of: * At diagnosis: multimodal treatment with neoadjuvant chemotherapy, surgery and adjuvant chemotherapy * At relapse: chemotherapy Patients who meet the eligibility criteria will be randomly assigned (1:1) into one of the following treatment groups: * Experimental arm: regorafenib + best supportive care (BSC) maintenance (12 months maximum) * Standard arm: placebo + BSC (12 months maximum) A randomization procedure (centralized implementation of concealed random permuted blocks) will be used to obtain a balanced distribution of the setting of the disease (stratification factor): residual disease at diagnosis or at relapse after standard multimodal treatment. After their eligibility has been confirmed, patients will receive regorafenib or its matching placebo until disease progression, or for a maximum of 12 months, or unacceptable toxicity or willingness to stop, whichever occurs first. In case of radiological disease progression during treatment period, patients from the standard arm (placebo) who have unresectable disease will be allow to switch to experimental arm (regorafenib). After the switch, patients will be treated with regorafenib until disease progression or unacceptable toxicity or willingness to stop which occurs first. After the completion of the maintenance therapy (12 months) patients will be followed-up until the first radiological disease progression, unless a premature disease progression occurred. All patients will be followed-up until the data cut-off (12 months after the last randomization). The vital status will be updated once for all patients at the end of the study, based on patient's medical file. The end of the study will be 24 months after the last randomisation or at the end of treatment of the last patient under treatment (either blinded or open label) whichever occurs last.

Eligibility

Minimum Age: 12 Years

Eligible Ages: CHILD, ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Chu Besancon, Besançon, , France

Institut Bergonie, Bordeaux, , France

Centre Georges Francois Leclerc, Dijon, , France

Centre Oscar Lambret, Lille, , France

Centre Leon Berard, Lyon, , France

Hopital de La Timone, Marseille, , France

Icm Val D'Aurelle, Montpellier, , France

Hotel Dieu Nantes, Nantes, , France

Institut Curie, Paris, , France

Hôpital COCHIN, Paris, , France

Ico Rene Gauducheau, Saint-Herblain, , France

Chu Saint-Etienne, Saint-Priest-en-Jarez, , France

CHRU Hôpital Hautepierre, Strasbourg, , France

ICANS, Strasbourg, , France

Iuct Oncopole, Toulouse, , France

Institut Gustave Roussy, Villejuif, , France

Contact Details

Name: Mehdi BRAHMI

Affiliation: Centre Léon Bérard (Lyon)

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: